Aptevo Therapeutics (APVO) entered into a $60M equity line of credit agreement with Yorkville Advisors Global, LP, strengthening the Company’s financial flexibility as it continues to advance its clinical and preclinical pipeline of multispecific anti-cancer agents that are differentiated by design. The facility provides Aptevo with access to capital, allowing the Company to raise funds incrementally, at its discretion, and under market-based conditions. Further, an ELOC offers affordable capital financing with minimal fees and no warrants. Proceeds from the ELOC will be used to support ongoing clinical development, advance preclinical programs, and fund general corporate purposes.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APVO:
- Aptevo Therapeutics trading halted, news pending
- Aptevo Therapeutics Implements 1-for-18 Reverse Stock Split
- Upcoming Stock Splits This Week (December 29 to January 2) – Stay Invested
- Aptevo Therapeutics Announces Promising RAINIER Trial Results
- Aptevo Therapeutics presents preliminary results from Phase 1b/2 RAINIER study